Artículos del autor

solaci

Acute coronary syndromes

REVERSE-IT | Bentracimab: Progress on the Antidote for Ticagrelor in Emergency Scenarios

Optimizing an antiplatelet therapy after an acute coronary syndrome (ACS) aims at reducing the major adverse cardiac...
solaci -
Institutional News

Dr. Marco Valgimigli Presented the Outcomes of MASTER-DAPT in a New SOLACI Webinar

Re-watch our webinar on “New Evidence in the Treatment of HBR Patients: Balance of Ischemic and Bleeding...
solaci -
Coronary disease

Drug Eluting Stents: Does Strut Size Matter?

The benefit of first-generation Drug-Eluting Stents (DES) over Bare Metal Stents (BMS) is largely known. Moreover, technological...
solaci -
Acute coronary syndromes

Is Coronary Revascularization Useful in Renal Transplant Candidates?

Coronary artery disease is the main cause of death in patients with functioning renal transplant, reaching 30%,...
solaci -
Acute coronary syndromes

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in...
solaci -
Institutional News

Webinar SOLACI – Medtronic | Impossible Cases! Review of Complex and Controversial TAVR Cases

We invite the entire Latin American community to analyze challenging TAVR cases together with a panel of...
solaci -
Acute coronary syndromes

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to...
solaci -
Structural heart disease

Low Risk Patients: TAVR with Self-Expanding Valves Offers Similar Outcomes to Surgery Based on a Bayesian Analysis?

When compared against surgical valve replacement (SAVR) transcatheter aortic valve replacement (TAVR) has shown benefits across different...
solaci -